| abstract |
A composition suitable for the treatment of prostate cancer is provided. A combination of a 5 alpha reductase inhibitor and a selective estrogen receptor modulator (SERM) is provided. This combination consists of (1) prevention of prostate cancer onset, (2) prevention of recurrence of prostate cancer onset, suppression, suppression or reduction of incidence, (3) treatment of prostate cancer, (4) suppression, suppression or reduction of onset of prostate cancer. , (5) treatment of prostate cancer precancerous lesions, (6) suppression, suppression or reduction of prostate cancer precancerous lesions, (7) diseases caused by androgen deprivation in male patients with prostate cancer (eg, osteoporosis, fractures) Decrease in bone mineral density (BMD), body heat, and / or gynecomastia), reduction, suppression, prevention and / or treatment, (8) treatment of polycystic ovary syndrome, and polycystic It is useful for delaying onset, suppression, suppression, prevention and / or treatment of diabetes, breast cancer, endometrial cancer or cardiovascular disease in female patients with ovarian syndrome. [Selection figure] None |